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Abstract Myometrial invasion (MI) as a percentage (%MI),
categorized into <50 or ≥50 %, is an important predictor of
prognosis in endometrial carcinoma. Recent studies suggest
that tumor-free distance (TFD) to serosa and the absolute
depth of invasion (DOI) might be stronger predictors of prog-
nosis. Although reproducibility is important in clinical prac-
tice for patient prognostication and treatment, reproducibility
of these methods for the measurement of MI is largely un-
known. One or two slides from 50 patients with FIGO stage
I endometrioid endometrial carcinoma were viewed by seven
gynecological pathologists, who were requested to measure
%MI, TFD, and DOI. We categorized %MI as <50 % (includ-
ing no MI) or ≥50 %, TFD as ≤1.75 or >1.75 mm (including
no MI), ≤7 or >7 mm (including no MI), and ≤10 or >10 mm
(including no MI) and DOI as <4 mm (including no MI) or
≥4 mm. Light’s kappa for multi-rater agreement was calculat-
ed. The%MI, TFD, and DOI could bemeasured in 88, 83, and
79 % of cases, respectively. Kappa was 0.75 for %MI, 0.77,
0.73, and 0.69 respectively for TFD with cutoffs of 1.75, 7,
and 10 mm, and 0.59 for DOI. Pathologists reach substantial
agreement when measuring %MI and TFD and moderate
agreement when measuring DOI. The %MI can be measured
in more cases than TFD and DOI. This supports the use of
%MI in daily clinical practice, but future studies should com-
pare %MI and TFD more extensively, including inter-
observer variability.
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Introduction
Endometrial carcinoma is the most common gynecological
malignancy in developed countries, and its incidence is in-
creasing [1, 2]. Primary treatment of endometrial carcinoma
consists predominantly of hysterectomy and bilateral
salpingo-oophorectomy. Additional staging is typically under-
taken for non-endometrioid and high-grade endometrioid car-
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cinomas and when tumor stage is advanced. Most patients are
diagnosed with FIGO stage I disease and low-grade (grade 1
or 2) endometrioid histology and have a good prognosis [2].
After primary surgery, the decision to administer adjuvant
radiotherapy to prevent locoregional recurrences relies on
the presence of predictors of poor outcome, such as high tu-
mor grade, lymphovascular invasion, deep myometrial inva-
sion (MI), and patient age >60 years [2].
Traditionally, the percentage of myometrial invasion
(%MI), categorized as <50 or ≥50 %, is one of the parameters
used in the determination of the need for adjuvant radiothera-
py [3–5]. However, more recently, two other methods of mea-
suring MI have been proposed: tumor-free distance (TFD) to
serosa (the distance in millimeters between the deepest point
of invasion and the serosa) and absolute depth of invasion
(DOI, the distance in millimeters between the endometrial/
myometrial junction and the deepest point of MI). A study
comparing TFD and DOI and another study comparing
%MI, TFD, and DOI concluded that TFD is superior in
predicting disease extension as well as outcome [6, 7]. Two
comparable studies, on the other hand, have shown that DOI is
superior in predicting nodal involvement, recurrent disease,
and disease-related mortality [8, 9]. One study comparing
TFD and DOI concluded that DOI is a stronger predictor of
outcome, but TFD is easier to measure, but kappa statistics
were not reported [10].
If measurement of TFD or DOI is superior to that of %MI,
it might improve identification of high-risk patients and indi-
vidualization of adjuvant treatment. However, reproducibility
of these measurements is important to support their prognostic
value in daily clinical practice. Because all previous studies
were single-center studies and measurements were performed
by a limited number of pathologists, reproducibility of TFD
and DOI is currently unknown. Some studies have reported on
reproducibility of %MI, but only one study included kappa
statistics with a kappa value of 0.83 [11]. The aim of our study
was to assess inter-pathologist reproducibility of %MI, TFD,
and DOI.
Materials and methods
Included cases
Slides from patients treated for stage I endometrioid endome-
trial carcinoma at the Radboud university medical center
(Radboudumc), Nijmegen, the Netherlands, between January
1999 and December 2009 were reviewed by a gynecological
pathologist (JB).
All pathologists collaborating in the European Network for
Individualized Treatment of Endometrial Cancer (ENITEC)
were invited to participate in this study, and seven expressed
their interest. The sample size calculation was based on pre-
vious studies assessing reproducibility of the %MI measure-
ment, as the kappa for TFD and DOI measurements is un-
known [11–14]. Based on a kappa of 0.8 for %MI, we calcu-
lated that 50 cases should be included in order to have 90 %
assurance that the two-sided 95 % confidence interval would
be no more than 0.1 [11, 15].
Myometrial invasion measurement
All cases were assessed independently by seven expert gyne-
cological pathologists who work in large referral centers (AW,
KV, CB, SG, BD, WGM, and GT), using the same set of
slides. Scoring was performed according to the instructions
shown in Fig. 1. For every case, the presence of MI had to
be determined. In cases with MI, the three different methods
for MI, as shown in Fig. 2, needed to be scored %MI (not
measurable, <50 or ≥50 %), TFD (not measurable or the
Fig. 1 Scoring instructions
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number of millimeters from the deepest point of invasion to
the serosa), and DOI (not measurable or the number of milli-
meters from the endometrial/myometrial junction to the
deepest point of invasion). Moreover, a perception of the dif-
ficulty of each measurement (easy, moderate, or difficult) had
to be reported by each pathologist. There was also an option to
provide comments after every measurement.
Statistical analysis
For statistical analysis, %MI was categorized as <50 % (in-
cluding no invasion) or ≥50 %. Reproducibility of TFD was
calculated for all three previously reported cutoff values:
≤1.75 or >1.75 mm (including no invasion), ≤7 or >7 mm
(including no invasion), and ≤10 or >10 mm (including no
invasion) [6, 7, 9, 10]. Only one earlier study described a
cutoff for DOI, which was categorized as <4 mm (including
no invasion) or ≥4 mm [9].
Light’s Kappa for multi-rater agreement was calculated for
categorized %MI, TFD, and DOI scores, bootstrapped (1000
runs), and 95 % confidence intervals were calculated. Missing
scores were excluded in a pairwise fashion. Kappa was cate-
gorized into slight (0.01–0.20), fair (0.21–0.40), moderate
(0.41–0.60) substantial (0.61–0.80), or almost perfect (0.81–
0.99) agreement [16]. R statistical software was used to per-
form the calculations [17].
Results
Myometrial invasion measurement
The results of the measurements are shown in Table 1. As
there were 50 cases, measured by seven pathologists, a total
of 350 measurements were possible per method. In 95 % of
the 350 measurements, the pathologists were able to assess
whether or not there was MI, ranging from 82 to 100 % of
the 50 measurements per pathologist. For the %MI, TFD, and
DOI measurements, this was 88 % (64–98 %), 83 % (78–
88 %), and 79 % (24–100 %), respectively. For the presence
of MI and the measurement of TFD, the median number of
measurements per case available to calculate Light’s multi-
rater kappa was seven; for the %MI measurement, this was
6.5; and for the DOImeasurement, 6. Almost all cases had two
or more measurements per method, allowing calculation of a
kappa value. In four cases, it was impossible to calculate the
kappa value for the TFD measurement, because no or only
one measurement was performed.
Fig. 2 Drawing of the different measuring methods in an endometrial
carcinoma with <50 % myometrial invasion. The dotted lines show the
position of the endometrial/myometrial junction (EMJ), and the line
where the tumor would invade half of the myometrium (50 % MI). The
arrows show the absolute depth of invasion (A) and tumor-free distance
(B) measurements
Table 1 Characteristics and reproducibility of myometrial invasion
measurements
Number of cases 50
Measurements possible per method 350
Is there myometrial invasion?
Measurable 331 (95 %, range 82-100%)
Median measurements per case 7 (range 3-7)
No myometrial invasion 79 (24 %)
Myometrial invasion 252 (76 %)
Kappa (95 % confidence interval) 0.63 (0.5–0.78)
Percentage of myometrial invasion
Measurable 307 (88 %, range 64-98%)
Median measurements per case 6.5 (range 3-7)
Myometrial invasion <50 % 220 (72 %)
Myometrial invasion ≥50 % 87 (28 %)
Kappa (95 % confidence interval) 0.75 (0.60–0.87)
Tumor-free distance
Measurable 291 (83 %, range 78-88%)
Median measurements per case 7 (range 0-7)
Median tumor-free distance 7 mm (range 0.8-19mm)
Tumor-free distance >1.75 mm 273 (94 %)
Tumor-free distance ≤1.75 mm 18 (6 %)
Kappa (95 % confidence interval) 0.77 (0.60–0.90)
Tumor-free distance >7 mm 181 (62 %)
Tumor-free distance ≤7 mm 110 (38 %)
Kappa (95 % confidence interval) 0.73 (0.60–0.85)
Tumor-free distance >10 mm 137 (47 %)
Tumor-free distance ≤10 mm 154 (53 %)
Kappa (95 % confidence interval) 0.69 (0.54–0.79)
Depth of invasion
Measurable 275 (79 %, range 24-100%)
Median measurements per case 6 (range 2-7)
Median depth of invasion 5 mm (range 0.1-25 mm)
Depth of invasion <4 mm 156 (57 %)
Depth of invasion ≥4 mm 119 (43 %)
Kappa (95 % confidence interval) 0.59 (0.41–0.76)
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The pathologists reported MI in 76 % of the measure-
ments with a kappa of 0.63 and ≥50 % myometrial inva-
sion in 28 % of the measurements with a kappa of 0.75.
The median TFD was 7 mm (range 0.8 to 19 mm). TFD
was ≤1.75 mm in 6 %, ≤7 mm in 38 %, and ≤10 mm in
53 % of the measurements with kappa values of 0.77, 0.73,
and 0.69, respectively. Median DOI was 5 mm (range 0.1
to 25 mm), ≥4 mm in 43 % of the measurements with a
kappa of 0.59. Examples of cases with good or poor repro-
ducibility are shown in Fig. 3.
Difficulties in measuring myometrial invasion
Table 2 shows how the pathologists rated the difficulty of
the three measurements relative to the percentage of cases
measured. For the %MI, the number of measurements per-
formed with a reported difficulty was 211; for TFD, this
was 201; and for DOI, 189. The measurements were per-
ceived to be easy in 54 % for %MI, 72 % for TFD, and
24 % for DOI; they were moderate in 30 % for %MI, in
21 % for TFD, and in 43 % for DOI and difficult in 16 %
for %MI, in 7 % for TFD, and in 33 % for DOI. For all
three measurements, the kappa value of the perceived dif-
ficulty was smaller than 0.1.
Discussion
This study shows that gynecological pathologists reach
substantial agreement when measuring %MI and TFD
and modera te agreement when measur ing DOI.
Pathologists found measuring DOI more difficult than
measuring %MI and TFD.
Myometrial invasion measurement
It is widely accepted that high tumor grade, non-endometrioid
histology, lymphovascular space invasion, and deep
myometrial invasion are predictors of poor prognosis in endo-
metrial carcinoma and important parameters to decide on in-
dividualized treatment [2]. Althoughmany studies reported on
reproducibility of tumor grading and histological typing, re-
ports on reproducibility of assessment of MI and
lymphovascular invasion are limited [18–21]. One study re-
ported a Cohen’s kappa value of 0.83 for two pathologists
measuring myometrial invasion in 177 cases of endometrial
cancer [11]. Other studies determined the percentage of agree-
ment between pathologists when measuring MI, but without
calculating the kappa value. Ali et al. reported a discrepancy
between the original %MI and the specialist reviewer %MI
measurement in 12 % of endometrial cancer cases [14].
Jacques et al. reported discrepancies between MI measured
by the pathologist who reported the case and a reviewing
Fig. 3 Several examples of slides scored in this study. Slides a and b
were scored with little agreement concerning the DOI, and it was
commented that it was hard to distinguish the endometrial/myometrial
junction. Slides c and d on the other hand were scored with perfect
agreement for all measurements.
Table 2 Difficulty of the
myometrial invasion
measurements of cases with
myometrial invasion
%MI TFD DOI
Percentage measurable 88 % 83 % 79 %
Number of measurements with
MI and known difficulty
211 201 189
Percentage difficulty (range)
Easy 54 % (21–77%) 72 % (59–93%) 24 % (0–39% )
Moderate 30 % (23–54%) 21 % (4–50%) 43 % (28–68%)
Hard 16 % (0–29%) 7 % (0–23%) 33 % (24–64%)
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pathologist in 31.5 % of cases [12]. In that study, MI was
categorized as not present, less than one third, and equal to
or more than one third and discrepancies most commonly
resulted in upstaging from no to less than one third MI. A
comparable study by Chafe et al. described differences be-
tween the original pathology report and a review in 34 % of
226 cases, but the percentage of cases with discrepancies in
the categorization of %MI was not separately mentioned
[13]. Lindauer et al. assessed the prognostic value of the
TFD measurement in 153 cases, but the reproducibility
between two pathologists was only determined in five
cases [6].
We show that gynecological pathologists reach sub-
stantial agreement with respect to the presence of MI
and the measurement of %MI and TFD, and moderate
agreement with respect to the measurement of DOI [16].
Interestingly, for both %MI and TFD, reproducibility was
better than that for assessment of the presence of MI. This
is in line with the studies of Jacques et al. and Ali et al.,
who found most discrepancies between cases with no MI
and cases with superficial MI [12, 14]. Because the re-
vised 2009 FIGO staging system does not differentiate
between no MI and superficial MI, this finding does not
affect staging and has been shown to be of no clinical
significance [22].
In comparing agreement between pathologists with re-
spect to %MI, TFD, and DOI measurements, the best
agreement was reached when measuring TFD with a cut-
off of 1.75 mm. This was closely followed by the %MI
measurement and TFD with cutoffs of 7 and 10 mm. The
most relevant cutoff for TFD needs to be determined, but
the differences in reproducibility are small and probably
without clinical importance, as are the differences be-
tween the reproducibi l i ty of the %MI and TFD
measurements.
Measuring MI is more difficult in the presence of an
irregular endometrial/myometrial junction, of a polypoid
tumor, or of adenomyosis, and also when the pattern of
MI is unusual, such as diffusely infiltrative, or microcystic,
elongated, and fragmented (MELF) [12, 23–26]. Because
these are not yet regularly reported in daily clinical prac-
tice, this was beyond the scope of our study. However, it
would be interesting to analyze the effect of different inva-
sion patterns on the reproducibility of MI measurements.
Difficulties in measuring myometrial invasion
Pathologists found measurement of DOI more difficult
than that of %MI and TFD, which is reflected in the
lower average reproducibility of these measurements.
However, perception of difficulty per case varied widely
between pathologists, as reflected in a low kappa value.
Comments of the participating pathologists indicated
that sampling and sectioning of the endometrium and
myometrium varies between institutions. Nonetheless,
moderate to substantial agreement was obtained.
However, further standardization of the guidelines might
decrease inter-observer variability of these three measure-
ments, which might improve their prognostic value.
Possible improvements might be (1) standardization of
the method to open the uterus as well as the location
and direction in which the tissue samples are taken rela-
tive to the tumor, the myometrium, and the serosa; (2)
photographic documentation of the specimen; and (3)
standardization of identification of the deepest point of
invasion and the defini t ion of the endometr ial /
myometrial junction.
Strengths and weaknesses of this study
This is the largest study assessing inter-pathologist repro-
ducibility of MI measurement and the first assessing the
reproducibility of the TFD and DOI measurement.
Although the 95 % confidence intervals of the kappa
values were slightly wider than expected, in part due to
the fact that not all measurements were performed, they
remained acceptable. For a study on reproducibility in
daily practice, our use of slides from daily practice rather
than cases optimized for measurability makes the results
relevant for daily practice. A limitation is that these slides
were from one institution, while significant differences
exist between institutions regarding sectioning and mea-
suring procedures. Standardization of guidelines might
further improve inter-observer reproducibility.
Conclusions
We show that gynecological pathologists reach substantial
agreement whenmeasuring %MI and TFD, but only moderate
agreement when measuring DOI. Measurement of %MI and
TFD was perceived to be easier than DOI measurement and
%MI was the measure most often successful. This supports
the use not only of %MI but also of TFD. These two param-
eters merit further study, always by at least two pathologists as
this will provide insight in inter-observer variability.
Guidelines for gross examination, sectioning, and measuring
of MI should be standardized to improve the inter-observer
variability and improve on prognostic value.
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